Brain Bytes Offers Bite-Sized Neuroscience to a Broad Audience

A group of neuroscience students are taking science communication into their own hands, and broadcasting their discoveries to the world on YouTube. Brain Bytes, a talk show-style web series, tells the stories of neuroscience discoveries in a way that’s accessible to colleagues and neuroscience neophytes alike. “We realized that when we share our research, it’s usually at talks and conferences…
Read More
Researchers at Simon Fraser University have devised a fiendishly clever way to trick rats into getting inside a trap by exploiting their snacking preferences, the comfort of community, the promise of sexy fun time and even the cries of baby rodents to play on a mother’s instincts. Animal communication expert Gerhard Gries started by creating a food odorant that mimics…
Read More

siRNA Rescues Nonhuman Primates from Advanced Marburg and Ravn Virus Disease

Ebolaviruses and marburgviruses belong to the family Filoviridae and cause high lethality in infected patients. There are currently no licensed filovirus vaccines or antiviral therapies. The development of broad-spectrum therapies against members of the Marburgvirus genus, including Marburg virus (MARV) and Ravn virus (RAVV), is difficult because of substantial sequence variability. RNAi therapeutics offer a potential solution, as identification of…
Read More
bioLytical Laboratories has been announced as a finalist of Business in Vancouver’s 2017 BC Export Awards in the Emerging Exporter category. bioLytical is the developer and manufacturer of INSTI, an HIV test that provides results in 1 minute.  Headquartered in Richmond, bioLytical employs 60 people in BC in addition to a sales force in the US. “We sell the innovative INSTI technology in nearly…
Read More
Read the Publication  This week we profile a recent publication in Cell Reports from Dr. Connie Eaves (above, right), David Knapp (below, first), Nagarajan Kannan (below, second), and Davide Pellacani (above, left) at the Terry Fox Laboratories. Can you provide a brief overview of your lab’s current research focus? The current research focus of the Eaves’ lab is to develop and deploy a…
Read More
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new cancer therapies, today announced the appointment of Mr. Saiid Zarrabian as interim Chief Executive Officer. “DelMar is pleased to welcome Mr. Zarrabian as interim CEO at an important time for our company,” said Dr. Erich Mohr, DelMar’s Chairman of the Board. “Saiid’s experience in overseeing the growth of…
Read More
Zymeworks Inc., a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today announced it has executed a licensing agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The deal was facilitated by Johnson & Johnson Innovation. Under the terms of the licensing agreement, Zymeworks will provide Janssen…
Read More
There has been a recent interest in understanding how a western lifestyle can influence inflammatory disease.  Our study has shed light on the mechanism by which the gut microbiome can influence lung inflammation and highlights specific immunological pathways that are essential in this interaction. We show that gut dysbiosis can exacerbate allergic lung inflammation...
Read More
Peterson’s Lab Inc,. a developer of bioactive recombinant protein, announced that the Company entered into a strategic cooperation with Shanghai Corday Biotech Ltd. under which Shanghai Corday will assume responsibility, on an exclusive basis, for Peterson’s Lab’s brand promotion and branded prestige skin care products to consumers in China, Japan and South Korea. “Shanghai Corday Biotech gives the Company access to three of the…
Read More
The Trudeau government’s decision last month to name a federal science adviser should come as welcome news to anyone who supports principles like evidence-informed policy-making and broader initiatives that support Canada’s research and innovation sectors. The appointment of Dr. Mona Nemer, a distinguished molecular geneticist, comes at a time when Ottawa is preparing to invest $950 million in a network…
Read More